Publications 2005

Lagaraine, C., C. Hoarau, V. Chabot, F. Velge-Roussel, and Y. Lebranchu. 2005. Mycophenolic acid-treated human dendritic cells have a mature migratory phenotype and inhibit allogeneic responses via direct and indirect pathways. Int Immunol 17:351,

Beaudreuil, S., G. Lasfargues, L. Laueriere, Z. El Ghoul, F. Fourquet, C. Longuet, J. M. Halimi, H. Nivet, and M. Buchler. 2005. Occupational exposure in ANCA-positive patients: a case-control study. Kidney Int 67:1961 ;

Bourgoin, H., G. Paintaud, M. Buchler, Y. Lebranchu, E. Autret-Leca, F. Mentre, and C. Le Guellec. 2005. Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients. Br J Clin Pharmacol 59:18;

Buchler, M. , Y. Lebranchu, M. Beneton, Y. Le Meur, A. E. Heng, P. F. Westeel, C. le Guellec, F. Libert, L. Hary, P. Marquet, and G. Paintaud. 2005. Higher exposure to mycophenolic acid with sirolimus than with cyclosporine cotreatment. Clin Pharmacol Ther 78:34;

Buchler, M. , and A. Johnston. 2005. Seeking optimal prescription of cyclosporine ME. Ther Drug Monit 27:3.

Dragon-Durey, M. A., C. Loirat, S. Cloarec, M. A. Macher, J. Blouin, H. Nivet, L. Weiss, W. H. Fridman, and V. Fremeaux-Bacchi. 2005. Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 16:555;

Giral, M., J. M. Nguyen, G. Karam, M. Kessler, B. Hurault de Ligny, M. Buchler, F. Bayle, C. Meyer, Y. Foucher, M. L. Martin, P. Daguin, and J. P. Soulillou. 2005. Impact of graft mass on the clinical outcome of kidney transplants. J Am Soc Nephrol 16:261;

Halimi, J. M., I. Laouad, M. Buchler, A. Al-Najjar, V. Chatelet, T. S. Houssaini, H. Nivet, and Y. Lebranchu. 2005. Early low-grade proteinuria: causes, short-term evolution and long-term consequences in renal transplantation. Am J Transplant 5:2281;

Laouad, I., J. M. Halimi, M. Buchler, A. Al-Najjar, V. Chatelet, H. Nivet, and Y. Lebranchu. 2005. Recipient age and mycophenolate mofetil as the main determinants of outcome after steroid withdrawal: analysis of long-term follow-up in renal transplantation. Transplantation 80:872;

Laouad, I., M. Buchler, C. Noel, T. Sadek, H. Maazouz, P. F. Westeel, and Y. Lebranchu. 2005. Renal artery aneurysm secondary to Candida albicans in four kidney allograft recipients. Transplant Proc 37:2834. Laouad, I., M. Buchler, P. F. Weestel, Y. Lebranchu, C. Legendre, G. Choukroun, and E. Thervet. 2005. Replacement kidney lipomatosis after renal transplantation. Lebranchu, Y., J. M. Halimi, A. Bock, J. Chapman, B. Dussol, L. Fritsche, V. Kliem, F. Oppenheimer, E. Pohanka, M. Salvadori, M. Soergel, and G. Tufveson. 2005. Delayed graft function: risk factors, consequences and parameters affecting outcome-results from MOST, A Multinational Observational Study. Transplant Proc 37:345.

Legendre, C., S. M. Beard, A. Crochard, Y. Lebranchu, C. Pouteil-Noble, A. Richter, and I. Durand-Zaleski. 2005. The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation. Eur J Health Econ.

Nathanson, S., P. Cochat, J. L. Andre, C. Guyot, C. Loirat, H. Nivet, and G. Deschenes. 2005. Recurrence of nephrotic syndrome after renal transplantation: influence of increased Premaud, A., J. Debord, A. Rousseau, Y. Le Meur, O. Toupance, Y. Lebranchu, G. Hoizey, C. Le Guellec, and P. Marquet. 2005. A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil. Clin Pharmacokinet 44:837;

Proust, A., B. Guillet, I. Pellier, P. Rachieru, C. Hoarau, S. Claeyssens, C. Leonard, S. Charrier, W. Vainchenker, G. Tchernia, and J. Delaunay. 2005. Recurrent V75M mutation within the Wiskott-Aldrich syndrome protein: description of a homozygous female patient. Eur J Haematol 75:54;

Salvadori, M., A. Bock, J. Chapman, B. Dussol, L. Fritsche, V. Kliem, Y. Lebranchu, F. Oppenheimer, E. Pohanka, G. Tufveson, A. Rosati, X. Puig, and G. Corbetta. 2005. Impact of mycophenolate mofetil dose posttransplantation on 12-month renal function: analysis of the MOST database. Transplant Proc 37:2464;

Stefoni, S., K. Midtved, E. Cole, E. Thervet, S. Cockfield, M. Buchler, L. Toselli, L. M. Pallardo, F. P. Schena, H. Pilmore, M. Kessler, S. Chadban, and C. A. Carreno. 2005. Efficacy and safety outcomes among de novo renal transplant recipients managed by C2 monitoring of cyclosporine a microemulsion: results of a 12-month, randomized, multicenter study. Transplantation 79:577 ;